Navigation Links
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Date:6/22/2009

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2010. Under the terms of the research period extension, Wyeth's obligations to Trubion include collaboration research funding commitments of approximately $3.3 million in exchange for committed research services through Dec. 22, 2010.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

"We are pleased that Wyeth has extended the research period of our collaboration," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "Wyeth's ongoing commitment to the collaboration underscores the potential of our technology, and we look forward to continuing our efforts with Wyeth as we pursue the development of additional first-in-class and best-in-class compounds."

In December 2005, Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of TRU-015 and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20 that have been established pursuant to the agreement. Unless earlier terminated, the agreement will remain in effect on a product-by-product basis and on a country-by-country basis until the later of the date that any such product shall no longer be covered by a valid claim of a U.S. or foreign p
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
2. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
3. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
5. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... 2014 Texas Governor Rick Perry, ... A&M Health Science Center CEO Brett Giroir, M.D., ... and Human Services (HHS), State of Texas and ... influenza vaccine manufacturing facility in Bryan, Texas, which ... the Texas A&M Biocorridor – a rapidly evolving ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... was involved in the cloning of Dolly the sheep said ... coverage of embryonic stem cell research, which could be raising ... corner when they are at least a few years away. ... said news of the possibilities of human embryonic stem cell ...
... their best mind you, growing up was "Aftermath", an appropriate label ... 2006- Chicago. , ,As BIO 2006 - Chicago is still fresh ... the outcome, but so many others have already done so that ... more of the facts emerge (like the final attendance number). Suffice ...
... - A young company with a preventive solution to identity ... G. Steven Burrill Technology Business Plan Competition, but if area ... they better act quickly. , , Din and Newport ... plan. Khaja M. Din, president IPIC (Internet ...
Cached Biology Technology:Researchers say scientific reporting needs more perspective, less hype 2Researchers say scientific reporting needs more perspective, less hype 3BIO 2006 aftermath and a taste of bio-generics 2BIO 2006 aftermath and a taste of bio-generics 3BIO 2006 aftermath and a taste of bio-generics 4BIO 2006 aftermath and a taste of bio-generics 5BIO 2006 aftermath and a taste of bio-generics 6BIO 2006 aftermath and a taste of bio-generics 7BIO 2006 aftermath and a taste of bio-generics 8Winner of Burrill competition courted by North Carolina investors 2Winner of Burrill competition courted by North Carolina investors 3
(Date:9/19/2014)... study the unique bioelectric signaling system of the electric ... The OU researcher is working to understand how ... signals used to map the world around them. ... 500-600 discharges a second throughout their lives. The ... but necessary for survival. , "There is evidence that ...
(Date:9/19/2014)... , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... company focused on the growing m-commerce market, updates the "Wocket in ... in the lightweight and light middleweight weight classes, Vinny Pazienza ... was announced that Game of Thrones actor Ciaran ... with Children star Katey Sagal have been cast ...
(Date:9/18/2014)... located deep in the primitive brainstem has revealed how ... Harvard School of Medicine and the University at Buffalo ... the second "sleep node" identified in the mammalian brain ... to produce deep sleep. , Published online in August ... fully half of all of the brain,s sleep-promoting activity ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... for detecting cocaine –?made with inexpensive, off-the-shelf electronics –?has ... University of California, Santa Barbara. Two local high school ... The potential applications of the sensor are far-reaching and ... high school students made their own sensors and collected ...
... that highly active antiretroviral therapy (HAART) is very cost-effective, ... shows that reimbursement to physicians treating patients with HIV ... study findings are reported in the April 1 issue ... HAART has led to dramatic decreases in illness and ...
... the ends of bones where they meet in a ... can lead to degenerative disease. Treatments and experimental approaches ... but currently there is no method to fully restore ... delivery of therapeutic proteins to the injured site is ...
Cached Biology News:Portable cocaine sensor developed at UC Santa Barbara 2Portable cocaine sensor developed at UC Santa Barbara 3Study shows AIDS drugs cost-effective, care underfunded 2Study shows AIDS drugs cost-effective, care underfunded 3Stem cells from muscles can repair cartilage 2Stem cells from muscles can repair cartilage 3
Polyclonal Antibody to HADHB...
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
A431 cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: